Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind botulinum toxin A injection into corrugator supercilii for major depressive disorder
jRCTs051250002Recruiting
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial in major depressive disorder (MDD) comparing BTX-A injection arm with Saline placebo injection arm (2 arms). Started Feb 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCTs051250002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250002.